Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience
- 241 Downloads
Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, PhD and Ambra Corti; this assistance was supported by internal funds.
Compliance with Ethical Standards
No funding was received for the preparation of this manuscript.
Conflict of Interest
Paolo Bossi has received consulting fee from Roche. Lisa Licitra has received consulting fees from Eisai, BMS, MSD, Merck-Serono, BI, Novartis, AstraZeneca, Bayer, and Roche; research funding from Eisai, MSD, Merck-Serono, BI, Novartis, AstraZeneca, and Roche; and other financial support from Merck-Serono and Bayer.
- 5.Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16:716–28.CrossRefPubMedGoogle Scholar
- 7.Sekulic A, Hainsworth JD, Lewis KD, Oro AE, Gesierich A, Mortier L, et al. Vismodegib for advanced basal cell carcinoma: duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. J Clin Oncol. 2014;32:5s. (abstr 9081)Google Scholar
- 8.Brinkhuizen T, Reinders MG, van Geel M, Hendriksen AJ, Paulussen AD, Winnepenninckx VJ, et al. Acquired resistance to the hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014;71:1005–8.CrossRefPubMedGoogle Scholar
- 10.Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14:1175–82.CrossRefPubMedPubMedCentralGoogle Scholar